Otonomy Inc., of San Diego, said it completed enrollment in a phase II trial of Otiprio in patients with acute otitis externa, also known as swimmer's ear, with preliminary results demonstrating clinical feasibility for that label expansion indication. The one-month, open-label phase II trial enrolled a total of 75 pediatric and adult patients with unilateral acute otitis externa.